Modified CEA nucleic acid and expression vectors
Details for Australian Patent Application No. 2003223527 (hide)
International Classifications
Event Publications
7 August 2003 Complete Application Filed
Priority application(s): 60/370,972 09.04.02 US
27 November 2003 Application Open to Public Inspection
Published as AU-B-2003223527
15 January 2009 Alteration of Name
The name of the applicant has been altered to Therion Biologics, Inc.; Sanofi Pasteur Limited
15 January 2009 Assignment before Grant
Sanofi Pasteur Limited; Therion Biologics, Inc. The application has been assigned to Sanofi Pasteur Limited
15 January 2009 Application Accepted
Published as AU-B-2003223527
14 May 2009 Standard Patent Sealed
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2003223528-TREATMENT FOR TYPE 1 DIABETES BEFORE AND AFTER EXPRESSION OF PREDISPOSITION MARKERS.
2003223526-A GENE ABNORMALLY EXPRESSED IN AUTOIMMUNE DISEASES AND MALIGNANCIES
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser